Trial results for the Phase 2 study NCT06124807 investigating Mazdutide in adult participants with obesity or overweight were posted on ClinicalTrials.gov on 2026-04-21. The study demonstrated that participants receiving 16 mg Mazdutide achieved a mean body weight reduction of up to -22.3% at Week 48, compared to -0.047% for those on placebo.
Background
The study, titled "A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight," aimed to investigate weight management efficacy and safety with Mazdutide in adults diagnosed with obesity or overweight.
Trial design
The study NCT06124807 was a Phase 2 trial that enrolled 179 adult participants. The study investigated Mazdutide compared with placebo in individuals with obesity or who were overweight. Participants received either varying doses of Mazdutide (3/6 mg, 10 mg, or 16 mg) or placebo. The study duration was approximately 62 weeks.
Key results
The trial results showed dose-dependent reductions in body weight for Mazdutide compared to placebo across different time points.
- For "Percent Change From Baseline in Body Weight at Week 32":
- Placebo group showed a mean change of -0.85% (Standard Error: 0.787).
- 3/6 mg Mazdutide group showed a mean change of -7.33% (Standard Error: 0.937).
- 10 mg Mazdutide group showed a mean change of -15.6% (Standard Error: 0.744).
- 16 mg Mazdutide group showed a mean change of -18.1% (Standard Error: 0.965).
- For "Percent Change From Baseline in Body Weight at Week 48":
- Placebo group showed a mean change of -0.047% (Standard Error: 1.059).
- 3/6 mg Mazdutide group showed a mean change of -10.54% (Standard Error: 1.498).
- 10 mg Mazdutide group showed a mean change of -19.2% (Standard Error: 1.076).
- 16 mg Mazdutide group showed a mean change of -22.3% (Standard Error: 1.424).
- For "Change From Baseline in Body Weight" (Kilograms):
- Placebo group showed a mean change of -0.98 Kg (Standard Error: 0.882).
- 3/6 mg Mazdutide group showed a mean change of -7.79 Kg (Standard Error: 1.011).
- 10 mg Mazdutide group showed a mean change of -16.1 Kg (Standard Error: 0.779).
- 16 mg Mazdutide group showed a mean change of -19.2 Kg (Standard Error: 1.037).
What this means
The results from this Phase 2 trial indicate that Mazdutide led to substantial, dose-dependent reductions in body weight in adults with obesity or overweight. The consistent and significant weight loss observed across the different Mazdutide doses, particularly the -22.3% reduction with the 16 mg dose at Week 48, suggests its potential as an effective treatment option for weight management. These findings support further development of Mazdutide for this patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06124807, titled "A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight," were posted on 2026-04-21 on clinicaltrials.gov.